Clinical trials: Myeloid Malignancy
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference
- Trial name
- PREFER-HMA (NCT05883956)
- Testing
- Subcutaneous azacitidine, Oral decitabine/cedazuridine
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 13 people
- Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
Leukemia, Myelodysplastic Syndromes
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow stem cell transplant helps stop the growth of cancer cells. Chemotherapy and antithymocyte globulin stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00627666
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Asan Medical Center
Glioblastoma, Brain Tumor
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs)…
- Trial name
- NCT07003542
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Myelogenous, Chronic Phase
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia
Since the debut of imatinib, the first tyrosine kinase inhibitor(TKI), more than two decades ago, the prognosis of patients with chronic myelogenous leukaemia (CML) has continued to improve.
- Trial name
- NCT03131986
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Leukemia, Myeloid, Acute
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study.
- Trial name
- NCT03988205
- Testing
- Outpatient Care Model, CPX-351
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Medical College of Wisconsin
Leukemia
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00006122
- Testing
- cytarabine, etoposide, gemtuzumab ozogamicin
- Where
- 18 sites in Austria, Belgium and 5 more
- Volunteers
- 106 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
Primary Objective: 1. To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloblastic Leukemia, Leukemia
- Trial name
- NCT00504920
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Patients will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, patients will be given very strong doses of chemotherapy, which will kill all their existing stem cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia
- Trial name
- DOTTI (NCT01494103)
- Testing
- iCaspase9-transduced T cells, AP1903
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Leukemia
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2. The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin to patients with AML.
- Trial name
- NCT02096042
- Testing
- Brentuximab Vedotin, 5-Azacytidine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelocytic, Acute
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients…
- Trial name
- NCT01339910
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 32 sites in United States
- Volunteers
- 272 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia, Childhood
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics.
- Trial name
- NCT03846362
- Testing
- HSCT
- Where
- 2 sites in Russia
- Volunteers
- 500 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia, Adult
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and…
- Trial name
- NCT04752527
- Testing
- venetoclax combined with decitabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia
Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- CML0408 (NCT00769327)
- Testing
- imatinib mesylate, nilotinib, cytogenetic analysis
- Where
- 37 sites in Italy
- Volunteers
- 129 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myelogenous Leukemia - Chronic Phase
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.
- Trial name
- NCT04925141
- Testing
- Dasatinib Tablets
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anemia
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid…
- Trial name
- NCT00117624
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT03187288
- Testing
- CFI-400945 Fumarate
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.
- Trial name
- NCT01280786
- Testing
- Elesclomol Sodium
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Synta Pharmaceuticals Corp.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Early Palliative Care for Patients With Haematological Malignancies
Patients suffering from haematological disease present symptoms of discomfort and currently benefit from palliative care skills only for the management of their end-of-life.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large B Cell Lymphoma, Palliative Care
- Trial name
- CALVI (NCT03800095)
- Testing
- Early palliative care integration
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited